Systemic therapy for laryngeal carcinoma
Frontiers in Oncology · 04.03.2025 · 15
DOI: 10.3389/fonc.2025.1541385 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 04.03.2025. Verfasst von Thorsten Fuereder und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, Medical University of Vienna, Vienna, Austria. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Laryngeal squamous cell carcinoma (LSCC) accounts for 100,000 deaths worldwide each year. Despite multimodal treatment, outcomes for both high-risk locally advanced and recurrent/metastatic laryngeal carcinoma remain poor. Treatment intensification through induction chemotherapy has not improved overall survival, although it may contribute to larynx preservation. Consequently, multiple recent efforts have been made to integrate novel immunotherapies into the current treatment algorithm for LSCC. In particular, perioperative immunotherapy regimens appear to be the most promising approach for preserving laryngeal function and optimizing event-free and overall survival rates in the locally advanced setting. In the recurrent/metastatic setting, the 5-year overall survival rate is approximately 20% with pembrolizumab-based regimens. Primary and secondary resistance to immunotherapy is frequently observed in the majority of patients. Along with trials of checkpoint inhibitor monotherapy, combinatorial approaches with novel immunotherapies, bispecific antibodies, targeted therapies, and antibody-drug conjugates are being explored for the treatment of recurrent/metastatic laryngeal carcinoma. This article aims to discuss recent efforts to improve outcomes and quality of life for patients with locally advanced and recurrent/metastatic LSCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine I, Medical University of Vienna, Vienna, Austria.
- Department of Internal Medicine V (Hematology and Oncology), Medical University of Innsbruck, Innsbruck, Austria.
- Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
- Department of Medical Oncology, Antwerp University Hospital, Edegem, Belgium.
Zitieren
APA
Fuereder, T., Kocher, F., & Vermorken, J. B. (2025). Systemic therapy for laryngeal carcinoma. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1541385
Vancouver
Fuereder T, Kocher F, Vermorken JB. Systemic therapy for laryngeal carcinoma. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1541385
BibTeX
@article{Fuereder2025,
author = {Fuereder, Thorsten and Kocher, Florian and Vermorken, Jan Baptist},
title = {Systemic therapy for laryngeal carcinoma},
journal = {Frontiers in Oncology},
year = {2025},
volume = {15},
doi = {10.3389/fonc.2025.1541385}
}
EUVIMED